Immunomodulatory approaches for prevention and treatment of infectious diseases

Current Opinion in Microbiology

Volumn 16, Issue 5, 2013, Pages 590-595

  Nijnik, Anastasia ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; AV 7909; ELTROMBOPAG; ERITORAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; IMIQUIMOD; IMMUNOMODULATING AGENT; IMX 942; INFLIXIMAB; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 7; MONOCLONAL ANTIBODY; NATALIZUMAB; OMIGANAN; PALIVIZUMAB; PATTERN RECOGNITION RECEPTOR; PEXIGANAN; PHOSPHORYL LIPID A; PROBIOTIC AGENT; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THROMBOPOIETIN RECEPTOR; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BACTEREMIA; CATHETER INFECTION; CROHN DISEASE; DRUG EFFICACY; FOOT ULCER; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFECTION PREVENTION; INNATE IMMUNITY; LACTIC ACID BACTERIUM; META ANALYSIS; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PANDEMIC; PAPILLOMAVIRUS INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; SEPSIS; THROMBOCYTOPENIA; TUBERCULOSIS; ULCERATIVE COLITIS; VIRUS CELL INTERACTION;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DRUG DISCOVERY; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY;

EID: 84887625932     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2013.06.011     Document Type: Review

References (56)

1. Hancock R.E., Nijnik A., Philpott D.J. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol 2012, 10:243-254.
2. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., Bartlett J.G., Edwards J. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the infectious diseases society of america. Clin Infect Dis 2008, 46:155-164.
3. Levy S.B., Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004, 10(Suppl.):S122-S129.
4. Jiang X.R., Song A., Bergelson S., Arroll T., Parekh B., May K., Chung S., Strouse R., Mire-Sluis A., Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011, 10:101-111.
5. Wood P. Immunotherapy for primary immunodeficiency diseases. Med Clin North Am 2012, 96:433-454. ix.
6. Saylor C., Dadachova E., Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 2009, 27(Suppl. 6):G38-G46.
7. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008, 8:776-787.
8. Hotchkiss R.S., Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
9. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-cd28 monoclonal antibody tgn1412. N Engl J Med 2006, 355:1018-1028.
10. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010, 10:425-434.
11. Lyman G.H., Shayne M. Granulocyte colony-stimulating factors: finding the right indication. Curr Opin Oncol 2007, 19:299-307.
12. Herbst C., Naumann F., Kruse E.B., Monsef I., Bohlius J., Schulz H., Engert A. Prophylactic antibiotics or g-csf for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009, CD007107.
13. Waller E.K. The role of sargramostim (rhgm-csf) as immunotherapy. Oncologist 2007, 12(Suppl. 2):22-26.
14. Tillmann H.L., McHutchison J.G. Use of thrombopoietic agents for the thrombocytopenia of liver disease. Semin Hematol 2010, 47:266-273.
15. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., Boue F., Molina J.M., Rouzioux C., Avettand-Fenoel V., Croughs T., et al. Enhanced t cell recovery in hiv-1-infected adults through il-7 treatment. J Clin Invest 2009, 119:997-1007.
16. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., Battaglia C.A., Landay A.L., Pahwa S., Fischl M.A., Asmuth D.M., et al. Il-7 administration drives t cell-cycle entry and expansion in hiv-1 infection. Blood 2009, 113:6304-6314.
17. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of il-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
18. Yang Y.F., Zhao W., Xia H.M., Zhong Y.D., Huang P., Wen J. Long-term efficacy of interferon alpha therapy on hepatitis b viral replication in patients with chronic hepatitis b: a meta-analysis. Antiviral Res 2010, 85:361-365.
19. Friedman R.M. Clinical uses of interferons. Br J Clin Pharmacol 2008, 65:158-162.
20. Uhlin M., Andersson J., Zumla A., Maeurer M. Adjunct immunotherapies for tuberculosis. J Infect Dis 2012, 205(Suppl. 2):S325-S334.
21. Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., Brauns C., Weiden M., Hoshino Y., Bateman E., Rom W.N. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS ONE 2009, 4:e6984.
22. Kumar H., Kawai T., Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2009, 30:16-34.
23. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 2010, 9:293-307.
24. Tyring A.G.A, Rosen S.K.T. Beyond a decade of 5% imiquimod topical therapy. J Drugs Dermatol 2009, 8:467-474.
25. Rozy A., Chorostowska-Wynimko J. Bacterial immunostimulants-mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 2008, 76:353-359.
26. Ruah S.B., Ruah C., van Aubel A., Abel S., Elsasser U. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv Ther 2001, 18:151-162.
27. Spreafico R., Ricciardi-Castagnoli P., Mortellaro A. The controversial relationship between nlrp3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010, 40:638-642.
28. Lambrecht B.N., Kool M., Willart M.A., Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009, 21:23-29.
29. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., Aoki F., Ramjattan B., Shier R.M., Somani R., Barbier S., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374:1975-1985.
30. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. Cpg DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10:499-511.
31. Klinman D.M., Xie H., Ivins B.E. Cpg oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci 2006, 1082:137-150.
32. Krieg A.M. Cpg still rocks! Update on an accidental drug. Nucleic Acid Ther 2012, 22:77-89.
33. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., Ravindran R., Stewart S., Alam M., Kwissa M., Villinger F., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470:543-547.
34. Barochia A., Solomon S., Cui X., Natanson C., Eichacker P.Q. Eritoran tetrasodium (e5564) treatment for sepsis: review of preclinical and clinical studies. Expert Opin Drug Metab Toxicol 2011, 7:479-494.
35. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
36. Nijnik A., Hancock R.E.W. The roles of cathelicidin ll-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009, 16:41-47.
37. Fjell C.D., Hiss J.A., Hancock R.E., Schneider G. Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 2012, 11:37-51.
38. Velden W.J., van Iersel T.M., Blijlevens N.M., Donnelly J.P. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11). BMC Med 2009, 7:44.
39. Yang D., Chertov O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., Anderson M., Schroder J.M., Wang J.M., Howard O.M., Oppenheim J.J. Beta-defensins: linking innate and adaptive immunity through dendritic and t cell ccr6. Science 1999, 286:525-528.
40. Davidson D.J., Currie A.J., Reid G.S., Bowdish D.M., MacDonald K.L., Ma R.C., Hancock R.E., Speert D.P. The cationic antimicrobial peptide ll-37 modulates dendritic cell differentiation and dendritic cell-induced t cell polarization. J Immunol 2004, 172:1146-1156.
41. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., Cao W., Wang Y.H., Su B., Nestle F.O., Zal T., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
42. Chamilos G., Gregorio J., Meller S., Lande R., Kontoyiannis D.P., Modlin R.L., Gilliet M. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide ll37. Blood 2012, 120:3699-3707.
43. van Dissel J.T., Soonawala D., Joosten S.A., Prins C., Arend S.M., Bang P., Tingskov P.N., Lingnau K., Nouta J., Hoff S.T., Rosenkrands I., et al. Ag85b-esat-6 adjuvanted with ic31(r) promotes strong and long-lived mycobacterium tuberculosis specific t cell responses in volunteers with previous bcg vaccination or tuberculosis infection. Vaccine 2011, 29:2100-2109.
44. Easton D.M., Nijnik A., Mayer M.L., Hancock R.E. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends Biotechnol 2009, 27:582-590.
45. Cotter P.D., Hill C., Ross R.P. Bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005, 3:777-788.
46. Kindrachuk J., Jenssen H., Elliott M., Nijnik A., Magrangeas-Janot L., Pasupuleti M., Thorson L., Ma S., Easton D.M., Bains M., Finlay B., et al. Manipulation of innate immunity by a bacterial secreted peptide: lantibiotic nisin z is selectively immunomodulatory. Innate Immun 2013, 19:315-327.
47. van der Does A.M., Bergman P., Agerberth B., Lindbom L. Induction of the human cathelicidin ll-37 as a novel treatment against bacterial infections. J Leukoc Biol 2012, 92:735-742.
48. Wang T.T., Nestel F.P., Bourdeau V., Nagai Y., Wang Q., Liao J., Tavera-Mendoza L., Lin R., Hanrahan J.W., Mader S., White J.H. Cutting edge: 1,25-dihydroxyvitamin d3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173:2909-2912.
49. Lagishetty V., Liu N.Q., Hewison M. Vitamin d metabolism and innate immunity. Mol Cell Endocrinol 2011, 347:97-105.
50. Nnoaham K.E., Clarke A. Low serum vitamin d levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008, 37:113-119.
51. Martineau A.R., Timms P.M., Bothamley G.H., Hanifa Y., Islam K., Claxton A.P., Packe G.E., Moore-Gillon J.C., Darmalingam M., Davidson R.N., Milburn H.J., et al. High-dose vitamin d(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011, 377:242-250.
52. Morrow L.E., Gogineni V., Malesker M.A. Probiotic, prebiotic, and synbiotic use in critically ill patients. Curr Opin Crit Care 2012, 18:186-191.
53. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 2010, 16:2202-2222.
54. Siempos I.I., Ntaidou T.K., Falagas M.E. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:954-962.
55. Wells J.M., Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362.
56. Braat H., Rottiers P., Hommes D.W., Huyghebaert N., Remaut E., Remon J.P., van Deventer S.J., Neirynck S., Peppelenbosch M.P., Steidler L. A phase i trial with transgenic bacteria expressing interleukin-10 in crohn's disease. Clin Gastroenterol Hepatol 2006, 4:754-759.